9-year-old shark attack survivor speaks out
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 minutes ago
- Yahoo
Myosin Therapeutics Awarded $4.5 Million NCI Bridge Grant to Advance Phase I Trial of MT-125 in Glioblastoma
JUPITER, Fla., Aug. 19, 2025 /PRNewswire/ -- Myosin Therapeutics, a biotechnology company developing novel therapies for aggressive cancers, today announced it has been awarded a $4.5M Phase IIB Bridge Award from the National Cancer Institute's (NCI) Small Business Innovation Research (SBIR) program. The funding will support Myosin Therapeutic's Phase I STAR-GBM dose escalation and expansion trial of MT-125, a first-in-class novel small molecule therapeutic being evaluated in patients with newly diagnosed, MGMT unmethylated glioblastoma. Glioblastoma remains among the most lethal cancers, with median survival measured in months. MT-125 targets non-muscle myosin II, a critical driver of tumor cell invasion, proliferation and treatment resistance, representing a novel therapeutic approach that is distinct from existing standards of care. The STAR-GBM trial will assess the safety, tolerability, and pharmacokinetics of MT-125 in this patient population with significant unmet need. Exploratory endpoints include measures of efficacy, including progression-free survival and overall survival. The NCI SBIR program is one of the most competitive federal funding mechanisms for cancer-focused innovation, providing support to small businesses with technologies that have strong scientific merit, commercial potential, and a clear path to clinical impact. Bridge Awards, which require that matching funds from private capital be raised first, are reserved for companies with promising, later-stage projects that have already demonstrated significant technical progress and the potential to attract substantial private investment. "The NCI Bridge Award was perfectly timed to support our STAR-GBM trial, for which patient enrollment is set to begin in November," said Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics. "It will enable us to generate the data needed to position the program for later-stage development, potential partnerships, and future expansion into a wider range of patients. Our ultimate goal is to deliver a transformative treatment option for patients who currently face limited or inadequate therapeutic choices." About Myosin TherapeuticsMyosin Therapeutics is a Jupiter, FL-based biotechnology company spun out of The Wertheim UF Scripps Institute (formerly Scripps Research, Florida). The company is focused on developing therapies for neuroscience and oncology indications using a platform that targets molecular nanomotor proteins. For more information, visit Contact: contact@ View original content to download multimedia: SOURCE Myosin Therapeutics Inc.
Forbes
8 minutes ago
- Forbes
FDA Suggest Walmart Recalls Frozen Shrimp After Radiation Detected At Port
The Food and Drug Administration is warning that some Great Value brand frozen shrimp sold at Walmart could be contaminated with radioactive isotope Cesium-137 after Customs and Border Protection detected the substance in shipping containers at four major American ports and at least one sample of shrimp. Cesium-137 was detected in some frozen shrimp coming from Indonesia—but none that have been sold in stores yet. getty The FDA is investigating the potential contamination and has not 'confirmed the presence of contamination in any product in commerce,' they are still warning consumers to avoid eating shrimp that come from the same Indonesian producer BMS Foods. The FDA is recommending Walmart recall frozen shrimp coming from BMS Foods, and the retailer has not returned a request for comment from Forbes. This is a breaking story and will be updated.
CBS News
8 minutes ago
- CBS News
Walmart's Great Value shrimp has risk of radioactive contamination, FDA says
Some frozen shrimp sold at Walmart under the Great Value label are at risk of radioactive contamination and shouldn't be consumed, according to a warning from the U.S. Food and Drug Administration. The frozen shrimp were imported from Indonesian company PT. Bahari Makmur Sejati and sold at Walmart stores as Great Value brand frozen raw shrimp, the FDA said on Tuesday. The agency noted it has recommended that Walmart recall the product. Walmart didn't immediately respond to a request for comment. The shrimp could be contaminated with a radioactive isotope called Cesium-137, although the FDA said that no products as of yet have tested positive for it. The agency said it issued the warning about Walmart's Great Value shrimp after it had detected Cesium-137 in a single shipment of frozen shrimp from PT. Bahari Makmur Sejati. That shipment "did not enter U.S. commerce," the FDA said. Here's what to know about the warning. The FDA said that consumers "should not eat or serve certain lots of Great Value raw frozen shrimp from Walmart." The lots are: Consumers who bought the shrimp cited in the FDA's notice should throw it away, the agency said. "Distributors and retailers should dispose of this product and should not sell or serve this product," the FDA added. Cesium-137, or Cs-137, is the radioactive form of the element cesium, according to the U.S. Environmental Protection Agency. Produced by nuclear fission, it's used in medical devices and is also a byproduct of nuclear fission in nuclear reactors and weapons testing, the EPA notes. The Cesium-137 detected in the imported shrimp was about 68 Bq/kg, which the FDA said sits below its threshold of 1200 Bq/kg for "levels of concern" for imported foods. "At this level, the product would not pose an acute hazard to consumers," the FDA said in its warning notice. However, the FDA noted that repeated low-dose exposure to Cesium-137 carries an "elevated risk of cancer, resulting from damage to DNA within living cells of the body." It added, "Avoiding products like the shipment FDA tested with similar levels of Cs-137 is a measure intended to reduce exposure to low-level radiation that could have health impacts with continued exposure over a long period of time."
